Advancements in the delivery of chimeric antigen receptor (CAR) T-cell therapy have created growing urgency to expand access across diverse care settings. Since the FDA approved the first two CAR T-cell therapies in 2017 for acute lymphoblastic leukemia and non-Hodgkin lymphoma, the field has expanded to six approved therapies for certain hematologic malignancies.
These therapies have demonstrated the potential for durable remission and improved survival in patients with relapsed or refractory disease, while research continues to explore applications in solid tumors.
ACCC is supporting community cancer programs and practices by providing education and tools to strengthen care coordination, address implementation challenges, and help identify eligible patients for CAR T-cell therapy earlier in their treatment journey.
Discover the top barriers, facilitators, and opportunities shaping access to CAR T-cell therapy, including how programs can turn challenges into solutions.
Utilize this quick-reference tool for CAR T-cell therapy centers to communicate essential information with referring program’s following a patient’s treatment.
Publication: American Journal of Managed Care (AJMC)
Explore how global experts are advancing reimbursement reforms to expand equitable access to CAR T-cell therapy. This cross-Atlantic perspective, co-authored by ACCC Executive Director Meagan O’Neill, outlines barriers facing oncology programs in the US and Europe. Highlights include value-based models that can help more eligible patients receive potentially curative treatment.
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center’s community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.
This program is made possible by support from Kite Pharma, Johnson & Johnson Healthcare Inc., and Legend Biotech.
